Viridian Therapeutics, Inc.\DE (VRDN) stock
VRDNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30255% above fair value
$30.12+0.06 (+0.20%)
Close on Nov 18, 2026Market cap $3.41BP/E –Yield –
Viridian Therapeutics, Inc.\DE ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Viridian Therapeutics, Inc.\DE's ebitda for the twelve months ending Jun 30, 2026 was -$404.73M. For fiscal 2025 it was -$362.94M. The highest annual figure on record is -$49.00K in fiscal 2013.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$362.94M | – |
| FY2024 | Dec 31, 2024 | -$298.50M | – |
| FY2023 | Dec 31, 2023 | -$253.93M | – |
| FY2022 | Dec 31, 2022 | -$134.05M | – |
| FY2021 | Dec 31, 2021 | -$79.61M | – |
| FY2020 | Dec 31, 2020 | -$110.14M | – |
| FY2019 | Dec 31, 2019 | -$41.69M | – |
| FY2018 | Dec 31, 2018 | -$32.80M | – |
| FY2017 | Dec 31, 2017 | -$26.22M | – |
| FY2016 | Dec 31, 2016 | -$16.65M | – |
| FY2015 | Dec 31, 2015 | -$11.00M | – |
| FY2014 | Dec 31, 2014 | -$6.72M | – |
| FY2013 | Dec 31, 2013 | -$49.00K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$126.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$116.05M | – |
| Q4 FY2025 | Dec 31, 2025 | -$122.63M | – |
| Q3 FY2025 | Sep 30, 2025 | -$39.90M | – |
| Q2 FY2025 | Jun 30, 2025 | -$106.65M | – |
| Q1 FY2025 | Mar 31, 2025 | -$93.75M | – |
| Q4 FY2024 | Dec 31, 2024 | -$87.35M | – |
| Q3 FY2024 | Sep 30, 2024 | -$83.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$72.05M | – |
| Q1 FY2024 | Mar 31, 2024 | -$55.75M | – |
| Q4 FY2023 | Dec 31, 2023 | -$71.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$51.09M | – |
| Q2 FY2023 | Jun 30, 2023 | -$59.14M | – |
| Q1 FY2023 | Mar 31, 2023 | -$72.37M | – |
| Q4 FY2022 | Dec 31, 2022 | -$48.97M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.51M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.85M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.10M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.97M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$90.55M | – |
| Q3 FY2020 | Sep 30, 2020 | -$5.35M | – |
| Q2 FY2020 | Jun 30, 2020 | -$6.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.93M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.00M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.13M | – |
| Q2 FY2019 | Jun 30, 2019 | -$8.84M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.66M | – |
| Q4 FY2018 | Dec 31, 2018 | -$10.38M | – |
| Q3 FY2018 | Sep 30, 2018 | -$9.05M | – |
| Q2 FY2018 | Jun 30, 2018 | -$8.76M | – |
| Q1 FY2018 | Mar 31, 2018 | -$4.55M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.27M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.79M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.25M | – |
| Q1 FY2017 | Mar 31, 2017 | -$6.87M | – |
| Q4 FY2016 | Dec 31, 2016 | -$5.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.98M | – |
See a number that looks wrong?